These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 27282800)
1. The anti-tumor effect of folate-targeted liposome microbubbles loaded with oridonin as ultrasound-triggered tumor-targeted therapeutic carrier system. Wang C; Li W; Hu B J Drug Target; 2017 Jan; 25(1):83-91. PubMed ID: 27282800 [TBL] [Abstract][Full Text] [Related]
2. A novel conjunction of folate-targeted carbon nanotubes containing protohemin and oridonin-liposome loaded microbubbles for cancer chemo-sonodynamic therapy. Wang CJ; Wang HZ; Li W J Drug Target; 2019 Dec; 27(10):1076-1083. PubMed ID: 30836772 [TBL] [Abstract][Full Text] [Related]
3. Novel galactosylated biodegradable nanoparticles for hepatocyte-delivery of oridonin. Wang Y; Liu X; Liu G; Guo H; Li C; Zhang Y; Zhang F; Zhao Z; Cheng H Int J Pharm; 2016 Apr; 502(1-2):47-60. PubMed ID: 26911417 [TBL] [Abstract][Full Text] [Related]
4. Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin. Duan C; Gao J; Zhang D; Jia L; Liu Y; Zheng D; Liu G; Tian X; Wang F; Zhang Q Biomacromolecules; 2011 Dec; 12(12):4335-43. PubMed ID: 22077387 [TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-liposome-microbubble complexes as ultrasound-triggered therapeutic drug delivery carriers. Yan F; Li L; Deng Z; Jin Q; Chen J; Yang W; Yeh CK; Wu J; Shandas R; Liu X; Zheng H J Control Release; 2013 Mar; 166(3):246-55. PubMed ID: 23306023 [TBL] [Abstract][Full Text] [Related]
6. Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier. Chen G; Luo J; Cai M; Qin L; Wang Y; Gao L; Huang P; Yu Y; Ding Y; Dong X; Yin X; Ni J Molecules; 2019 Sep; 24(18):. PubMed ID: 31527488 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antitumor activity of oridonin nanosuspension. Lou H; Zhang X; Gao L; Feng F; Wang J; Wei X; Yu Z; Zhang D; Zhang Q Int J Pharm; 2009 Sep; 379(1):181-6. PubMed ID: 19563872 [TBL] [Abstract][Full Text] [Related]
8. Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers. Leng X; Dong X; Wang W; Sai N; Yang C; You L; Huang H; Yin X; Ni J Molecules; 2018 Sep; 23(10):. PubMed ID: 30274195 [TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin. Li C; Zhang D; Guo H; Hao L; Zheng D; Liu G; Shen J; Tian X; Zhang Q Int J Pharm; 2013 May; 448(1):79-86. PubMed ID: 23518367 [TBL] [Abstract][Full Text] [Related]
10. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption. Zhou X; Zhang X; Ye Y; Zhang T; Wang H; Ma Z; Wu B Int J Pharm; 2015 Feb; 479(2):391-8. PubMed ID: 25556104 [TBL] [Abstract][Full Text] [Related]
11. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin. Zheng D; Duan C; Zhang D; Jia L; Liu G; Liu Y; Wang F; Li C; Guo H; Zhang Q Int J Pharm; 2012 Oct; 436(1-2):379-86. PubMed ID: 22732673 [TBL] [Abstract][Full Text] [Related]
13. In vivo studies on the oridonin-loaded nanostructured lipid carriers. Zheng D; Dai W; Zhang D; Duan C; Jia L; Liu Y; Zhang Q Drug Deliv; 2012 Aug; 19(6):286-91. PubMed ID: 22928767 [TBL] [Abstract][Full Text] [Related]
14. GE11 peptide conjugated selenium nanoparticles for EGFR targeted oridonin delivery to achieve enhanced anticancer efficacy by inhibiting EGFR-mediated PI3K/AKT and Ras/Raf/MEK/ERK pathways. Pi J; Jiang J; Cai H; Yang F; Jin H; Yang P; Cai J; Chen ZW Drug Deliv; 2017 Nov; 24(1):1549-1564. PubMed ID: 29019267 [TBL] [Abstract][Full Text] [Related]
15. Chitosan-g-poly(N-isopropylacrylamide) based nanogels for tumor extracellular targeting. Duan C; Zhang D; Wang F; Zheng D; Jia L; Feng F; Liu Y; Wang Y; Tian K; Wang F; Zhang Q Int J Pharm; 2011 May; 409(1-2):252-9. PubMed ID: 21356283 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo antitumor effects of folate-targeted ursolic acid stealth liposome. Yang G; Yang T; Zhang W; Lu M; Ma X; Xiang G J Agric Food Chem; 2014 Mar; 62(10):2207-15. PubMed ID: 24528163 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of oridonin-loaded long circulating nanostructured lipid carriers. Jia L; Shen J; Zhang D; Duan C; Liu G; Zheng D; Tian X; Liu Y; Zhang Q Int J Biol Macromol; 2012 Apr; 50(3):523-9. PubMed ID: 22301003 [TBL] [Abstract][Full Text] [Related]
18. Comparative studies on glycerol monooleate- and phytantriol-based cubosomes containing oridonin in vitro and in vivo. Shi X; Peng T; Huang Y; Mei L; Gu Y; Huang J; Han K; Li G; Hu C; Pan X; Wu C Pharm Dev Technol; 2017 May; 22(3):322-329. PubMed ID: 26670780 [TBL] [Abstract][Full Text] [Related]
19. Oridonin-loaded poly(epsilon-caprolactone)-poly(ethylene oxide)-poly(epsilon-caprolactone) copolymer nanoparticles: preparation, characterization, and antitumor activity on mice with transplanted hepatoma. Feng N; Wu P; Li Q; Mei Y; Shi S; Yu J; Xu J; Liu Y; Wang Y J Drug Target; 2008 Jul; 16(6):479-85. PubMed ID: 18604660 [TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation. Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J; Niu R Pharm Res; 2010 Sep; 27(9):1914-26. PubMed ID: 20582454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]